Israel Active

Israel’s DeepDense has developed Plug-AI – smart tools to enhance the digital images produced by other medical companies. DeepDense has teamed up with US firm Spectrum Dynamics Medical to improve the quality of cardiac and spinal images and reduce scan times.

The Prism electrodes-laden cap from Israel’s GrayMatters Health (see previously) has been added to the PTSD treatments offered by two major US clinics - Home Base and Fermata. Prism helps patients control PTSD symptoms by displaying brain activity.

Dr. Idit Maya, Head of the Genomic School at Beilinson Hospital explains how the body need to use different proteins to perform different functions. These proteins can be generated by making changes at the cellular level. In the future, new skills can be taught with the help of biological tools.

Doctors at Israel’s Beilinson Hospital have demonstrated the effectiveness of treating prostate cancer with two doses of high-dose external beam radiation instead of the current five doses. Benefits include less physical and emotional toll, less side effects, and shorter wait times.

Israel’s Alpha Tau Medical (see previously) has treated its first patient with recurrent lung cancer using its innovative Alpha DaRT® alpha-radiation cancer therapy. The WHO reports 2.5 million new lung cancer cases annually and the most cancer-related deaths.

Scientists at Israel’s Weizmann Institute have uncovered how aging cells evade the immune system. The protein PD-L1 stops the immune system from recognizing and destroying aging (senescent / “zombie”) cells. Antibodies to PD-L1 reduced inflammation and numbers of senescent cells.

Psifas is the Israeli Genome project. With a budget of NIS 250 million, it aims to create a genetic database of 100,000 Israel’s citizens. The information collected from patients of the Clalit health company, already provides information that will make it possible to treat life-threatening diseases.

The brain’s NMDA receptor (NMDAR) is known to be vital for learning and memory. Now Tel Aviv University researchers have discovered that it also maintains stable brain function during environment and physiological changes. The discovery may lead to new treatments for brain diseases.

Tel Aviv University researchers have discovered a mutation of the TMEM16F protein secretes α-synuclein to enhance the spread of Parkinson’s pathology through nerve cells in the brain. Blocking or modulating TMEM16F activity may reduce α-synuclein and cure Parkinson’s disease.

Researchers from Tel Aviv University and Shamir Medical Center in Beer Yaakov found that hyperbaric oxygen therapy (HBOT) can significantly alleviate PTSD symptoms, particularly for patients unresponsive to traditional therapies or medications.